Trial Profile
A Phase III double-blind, double-dummy, placebo-controlled, 8 week fixed dose trial with pramipexole IR (Mirapex, Mirapexin, Pexola, Sifrol) 0.125 and 0.5 mg/day administered orally to investigate the efficacy and safety in patients 6-17 years of age diagnosed with Tourette Syndrome according to DSM-IV criteria
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 May 2011
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Therapeutic Use
- 31 May 2011 New trial record